Form 4: Ocular Therapeutix Executive Pre-Reports Future Stock Transactions

Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, pre-reported future sales for tax obligations and a transfer of shares to an irrevocable trust.

Summary

• Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, Inc. (OCUL), filed a Form 4 reporting future transactions.
• On November 24, 2025, 19,530 shares of common stock are scheduled to be sold at a weighted average price of $12.04 per share, with prices ranging from $11.74 to $12.34.
• This sale is pursuant to a durable automatic sale instruction adopted on February 21, 2024, under Rule 10b5-1(c), to satisfy tax withholding obligations related to the vesting of restricted stock units on November 22, 2025.
• Following this sale, Dugel will directly beneficially own 3,157,960 shares of common stock.
• On November 26, 2025, Dugel's spouse will transfer 49,754 shares of common stock for no consideration to the Pravin Dugel 2024 Irrevocable Trust.
• Dugel is the trustee and sole beneficiary of this Trust during his lifetime, thus remaining the beneficial owner of these securities.
• Following this transfer, the Trust will indirectly beneficially own 300,115 shares of common stock.

Sentiment

Score: 5

Explanation: The transactions are routine and pre-planned (tax-related sale, trust transfer) and do not indicate a change in management's view of the company's prospects. The filing pre-reports future transactions, which is standard for 10b5-1 plans.

Future Outlook

The filing details future, pre-planned transactions under a Rule 10b5-1 plan and an estate planning transfer, but does not provide any forward-looking statements or guidance regarding the company's operational or financial performance.

Industry Context

This Form 4 filing reports routine insider transactions (a pre-planned 'sell-to-cover' for tax obligations and an estate planning transfer) and does not provide information relevant to broader industry trends or competitive landscape.

Related Party Transactions

• The transfer of 49,754 shares from the reporting person's spouse to the Pravin Dugel 2024 Irrevocable Trust, where Pravin Dugel is the trustee and sole beneficiary, represents a transaction involving related parties.

Stakeholder Impact

• Minimal direct impact on shareholders as these are routine insider transactions (tax-related sale, estate planning transfer) and not discretionary sales indicating a lack of confidence in the company's future.

Key Dates

Recommendation

The reported transactions are routine insider disclosures, including a pre-planned 'sell-to-cover' for tax obligations and a transfer to an irrevocable trust for estate planning. These are not discretionary sales reflecting a change in management's outlook on the company's fundamentals. Therefore, the filing itself does not provide new information to warrant a change in investment recommendation.

Keywords

Ocular Therapeutix, OCUL, Form 4, Insider Transaction, Stock Sale, Trust Transfer, Pravin Dugel, Executive Chairman, CEO, Restricted Stock Units, Tax Withholding, 10b5-1 Plan